Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer
NCT ID: NCT03239626
Last Updated: 2025-01-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
120 participants
INTERVENTIONAL
2017-08-31
2025-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postoperative Hypofractionated Intensity-modulated Radiation Therapy with Concurrent Chemotherapy in Cervical Cancer
NCT03239613
Intensity-modulated Radiotherapy Protocol in Cervix Cancer
NCT02993653
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients
NCT00359866
Sonographic Characteristics of Tumor Indices in Patients With Cervical Cancer During Chemo-radiotherpy
NCT01562067
HPV Serum Level and FDG PET CT in Patients With Cervical Cancer Treated With Radical Radiochemotherapy
NCT04683549
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
POHIM-RT
adjuvant hypofractionated IMRT for cervical cancer patients
POHIM-RT
postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
POHIM-RT
postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* radical hysterectomy and pelvic lymph node dissection was done
* histologically indicated adjuvant radiotherapy ( more than one as below)
1. tumor size ≥4 cm
2. positive lymphovascular invasion
3. more than half stromal invasion depth
* ECOG performance status 0 or 1
* Bone marrow function: granulocyte ≥1.0 x 1000/µl, platelet ≥30 x 1000/µl, hemoglobin ≥10 g/dl
Exclusion Criteria
* positive distant metastasis (including retroperitoneal lymph node metastasis)
* positive tumor involvement on resection margin
* positive parametrial invasion
* previous history of pelvic radiotherapy
* more than 3 months after radical surgery for cervical cancer
* neoadjuvant chemotherapy was done
* previous history of other carcinoma except for thyroid cancer, skin cancer, in situ carcinoma on cervix
20 Years
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Won Park, M.D.,Ph.D
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cho WK, Park W, Kim SW, Lee KK, Ahn KJ, Yoon M, Choi JH. Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study). Gynecol Oncol. 2025 Jul;198:84-89. doi: 10.1016/j.ygyno.2025.05.020. Epub 2025 May 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMC 2017-03-092-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.